Cite
HARVARD Citation
Omar, H. et al. (2018). Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt. Alimentary pharmacology & therapeutics. 47 (3), pp. 421-431. [Online].